Robert M. Palladino named as Chief Financial Officer, Dr. Yatindra Joshi as Special Advisor to the Board of Directors to accelerate Strategic Growth Plan activities.
WILMINGTON, Mass. (August 1, 2017) – CutisPharma today announced the appointments of Robert M. Palladino as Chief Financial Officer and Yatindra Joshi, Ph.D., as a Special Advisor to the Board of Directors.
“With our recent filing of our first New Drug Application (NDA) submission to the FDA, I am pleased to have Bob on my management team as our first CFO and Yatindra on our Board to assist in executing our long-term growth plans,” said Neal I. Muni, MD, MSPH, Chief Executive Officer of CutisPharma. “Their strategic acumen and deep background in the pharmaceutical industry provide the company with valuable insight and capabilities to achieve our goals.”
Palladino has over 35 years of global strategic and operating experience in the life sciences industry. He has served as CFO for 480 Biomedical, Claritas Genomics, BioNevia, Corrona, PatientsLikeMe and Biosphere Medical. Palladino also founded Oxus Medical (oximetry in cardiac resynchronization) and Tesa Medical (orthopedics).
“I am excited to join CutisPharma at such an important inflection point in its history,” said Palladino. “The Company has had a great track record of fully executing on its ambitious growth plans to date, and I look forward to supporting the Company’s expansion.”
Joshi is a Partner at YMJ Consultants LLC. He also serves as Chairman of the Board of Neoprol Ltd. and is a member of the Board of Directors of Tapemark, InvaGen and Virtus Pharmaceuticals. Joshi has over 30 years of pharmaceutical industry experience, including Senior Vice President, Generic R&D – North America, at Teva Pharmaceuticals, and senior leadership roles at Bristol-Myers Squibb and Novartis.
“The CutisPharma story and the quality of its management team are quite impressive, and I look forward to my role in advising the Company’s Board to help optimize its strategic positioning in the industry,” said Joshi. “The Company has innovated by creating a specialized platform in an underserved niche of the pharmaceutical industry, and is benefiting greatly from its position.”
CutisPharma has recently undertaken several significant initiatives to expand the business from its historical base in the pharmacy compounding market and toward development and commercialization of FDA-approved drugs. The filing of the Company’s first NDA, by its ℞M Therapeutics subsidiary, is a key milestone in the Company’s expansion goals.
CutisPharma, Inc., based in Wilmington, Mass., is a privately held, specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications for nearly 20 years. The Company’s products include oral solutions and suspensions, such as antimicrobials, mouthwashes, and PPIs; topicals, including hydrocortisone; and suppositories, including progesterone VGS. The Company’s FI℞ST® Unit-of-Use Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by commercially available therapies. For more information, visit www.cutispharma.com.
About ℞M Therapeutics
℞M Therapeutics, a wholly owned subsidiary of CutisPharma, is focused on developing and commercializing FDA-approved drugs to meet the needs of patients, such as children and the elderly, who are unable to take tablets and capsules and need a high quality, palatable alternative formulation of therapy to address their needs.
Contact: Greg Turner, Ball Consulting Group, LLC